

MDHHS – MCIR Release Notes

Version 2024 – MCIR OLTP 2024 24.3.27 – RFC 233707

Release Date: 03/27/2024

Forecasting & Assessment – 3 Items

1. Dose 3 PCV should forecast for at least 12 months of age and at least 8 weeks as final dose if previous dose is 7-11 months of age. (Ref# 292)

Personal Information/Status						
Name	DOB					Assessment indicates that vaccinations are overdue and should be administered today if not medically contraindicated.
Patient ID	Age	1 Year 8 Months				
Administered Vaccine	Can be given today	Dose #	Accelerated	Recommended	Overdue	
Pneumococcal PCV13/PCV15/PCV20	YES	3	06/29/2023	06/29/2023	09/27/2023	
<div style="display: flex; justify-content: space-around;"> Add to Roster Unlock Person Reassess Person </div>						

Series	Immunizations						Other	Status
	Dose 1	Dose 2	Dose 3	Dose 4	Dose 5	Dose 6+		
Pneumococcal Conjugate	02/13/2023 PCV13 (Prenar13) 7mos 15dys	04/27/2023 PCV15 (VAXNEUVANCE) 9mos 29dys					Pneumococcal PCV13/PCV15/PCV20 DUE NOW	

2. Td/Tdap booster should be 10 years for accelerated date. (Ref# 2588)

Series	Immunizations						Other	Status
	Dose 1	Dose 2	Dose 3	Dose 4	Dose 5	Dose 6+		
TP/DTaP/DT/Td/Tdap	06/05/2017 DTaP-IPV 3yrs 8mos	09/21/2017 DTaP (pediatric) 3yrs 11mos	03/23/2018 DTaP (pediatric) 4yrs 5mos	03/19/2024 Tdap (adol/adult) 10yrs 5mos			Up-To-Date Next Due 03/19/2034	

Personal Information/Status						
Name	DOB					Assessment indicates that vaccinations are overdue and should be administered today if not medically contraindicated.
Patient ID	Age	10 Years 5 Months				
Administered Vaccine	Can be given today	Dose #	Accelerated	Recommended	Overdue	
Td/Tdap		5	03/19/2029	03/19/2034	04/15/2034	

3. Update RSV MAB forecasting and evaluation, review RSV vaccine for 24-25 season will become effective on 4/1/2024 (Ref# 2767)
 - RSV season is defined as October 1, 2024, through March 31, 2024, for 0 to 8 months of age.
 - Doses given to infants with special situations, who are 8 -19 months, will be accepted and displayed as Other Administrations.
 - RSV vaccine forecast for unvaccinated adults 60 years and older was updated changed to 9/1/24 (late summer or early fall) for unvaccinated adults


RSV	Consider	09/01/2024	09/01/2024	09/01/2024
-----	----------	------------	------------	------------

- For more information, go to <https://www.cdc.gov/vaccines/vpd/rsv/hcp/child-faqs.html>.

Please review the links provided below for the updated CDC information.
[RSV \(Respiratory Syncytial Virus\) Immunizations | CDC](#)
[RSV Vaccination: What Older Adults 60 Years of Age and Over Should Know | CDC](#)
[Healthcare Providers: RSV Vaccination for Adults 60 Years of Age and Over | CDC](#)
[Frequently Asked Questions About RSV Vaccine for Adults | CDC](#)
[Preventing RSV \(Respiratory Syncytial Virus\) | CDC](#)
[RSV in Older Adults and Adults with Chronic Medical Conditions | CDC](#)
[For Healthcare Professionals: RSV \(Respiratory Syncytial Virus\) | CDC](#)

General - 2 items

1. CVX 30 HepB IG manufacturer's list has been updated to add **Grifols** Therapeutics. (Ref# 2795)



The screenshot shows a 'Product Details' form. The 'Vaccine*' field is set to 'HBIG: Hep B globulin'. The 'Mfr*' dropdown is open, showing a list of manufacturers: 'Biotest', 'Grifols' (highlighted in yellow), and 'NABI'. Other fields include 'NDC Unit of Sale*', 'Product Name*', 'Qty/Pkg*', 'Min Dose Qty', 'NDC Unit of Use*', 'Abbreviation', and 'Description'.

2. The issue with HL7 Rejection resulting in deduction from Beyfortus inventory has been resolved. (Ref# 2744)

Upon receipt of a rejection messages, the information will not appear on the patient's record or deduct from inventory.

If you have questions or need assistance, please contact your Field Representative or **MCIR SOM Help Desk** at MDHHS-MCIRHelp@michigan.gov.